GlassScriptPhysician profile
Marsha Pratt
NPI 1932366713
$162.52
in general payments reported to CMS, 2019-2025
8 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $144 · 2020: $18.62.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $31.11 | 2019 | |
| Puma Biotechnology, INC. | $29.20 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $24.13 | 2019 | |
| Astellas Pharma US INC | $18.62 | 2020 | |
| Celgene Corporation | $17.41 | 2019 | |
| Alexion Pharmaceuticals, INC. | $15.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $14.27 | 2019 | |
| Genzyme Corporation | $11.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marsha Pratt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.